This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azuma, A. Articles by Niitani, H. Search for Related Content PubMed PubMed Citation Articles by Azuma, A. Articles by Niitani, H.

Induction of Intercellular Adhesion Molecule 1 on Small Cell Lung Carcinoma Cell Lines by -Interferon Enhances Spontaneous and Bispecific Anti-CD3 x Antitumor Antibody-directed Lymphokine-activated Killer Cell Cytotoxicity

Fourth Department of Internal Medicine, Nippon Medical School [A. A., H. N.], 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113, and Department of Immunology, Juntendo University School of Medicine [A. A., H. Y., H. M., K. O.], 3-1-3 Hongo, Bunkyo-ku, Tokyo 113, Japan

The interaction between LFA-1 and its natural ligand, ICAM-1, plays an important role in leukocyte adhesion and signal transduction. LFA-1-mediated T-cell adhesion is generally activated by CD3-mediated signal in association with T-cell receptor-mediated recognition of the antigen/major histocompatibility complex on antigen-presenting cells. In the present study, we compared spontaneous or bispecific antibody (BsAb)-directed LAK cell cytotoxicity against ICAM-1⁺ or ICAM-1^- small cell lung cancer (SCLC) cell lines. -Interferon (IFN-)-induced ICAM-1 expression on ICAM-1^- SCLC cell lines, and susceptibility to LAK cells was increased simultaneously. Increased cytolysis of the IFN--treated SCLC was inhibited by an anti-ICAM-1 monoclonal antibody (mAb). Furthermore, LAK cell cytotoxicity directed by BsAb, which was composed of OKT3 and anti-SCLC mAb, was also increased by the IFN- treatment of SCLC, and this increase was inhibited by an anti-ICAM-1 mAb but not by anti-Class I or anti-CD2 mAb. These results suggest that a prior administration of IFN- would enhance the efficacy of the following specific targeting therapy utilizing BsAb and LAK cells by up-regulating the ICAM-1 expression on tumor target cells. The combinational use of IFN- and anti-CD3 x anti-tumor BsAb might be a promising way of enhancing LAK cell-mediated adoptive immunotherapy in small cell lung cancer patients.

¹ to whom requests for reprints should be addressed, at 4th Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113, Japan.

Received 10/30/91. Accepted 7/ 7/92.

This article has been cited by other articles:

				R. Parasole, F. Izzo, F. Perrone, S. Pignata, M. G. Galati, E. Leonardi, F. Castiglione, R. Orlando, G. Castello, G. Esposito, et al. Prognostic Value of Serum Biological Markers in Patients with Hepatocellular Carcinoma Clin. Cancer Res., November 1, 2001; 7(11): 3504 - 3509. [Abstract] [Full Text] [PDF]

				P. Ghia, P. Transidico, J. P. Veiga, C. Schaniel, F. Sallusto, K. Matsushima, S. E. Sallan, A. G. Rolink, A. Mantovani, L. M. Nadler, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells Blood, August 1, 2001; 98(3): 533 - 540. [Abstract] [Full Text] [PDF]

				M. Yasuda, Y. Tanaka, M. Tamura, K. Fujii, M. Sugaya, T. So, M. Takenoyama, and K. Yasumoto Stimulation of {beta}1 Integrin Down-Regulates ICAM-1 Expression and ICAM-1-dependent Adhesion of Lung Cancer Cells through Focal Adhesion Kinase Cancer Res., March 1, 2001; 61(5): 2022 - 2030. [Abstract] [Full Text]